A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Patients With Acute Schizophrenia (PREVAIL)

• Change from baseline in Positive And Negative Syndrome Scale (PANSS) [ Time Frame: Baseline (Week 0), Week 1, Week 5, Week 13 ] [ Designated as safety issue: No ]
  The PANSS is scale of 30 items which includes 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items). The scale ranges from 1 (absent) to 7 (extreme).
  
  

• Number of patients with at least a 30% reduction from baseline in Positive and Negative Syndrome Scale (PANSS) total score [ Time Frame: Baseline, Week 1, Week 5, Week 13 ] [ Designated as safety issue: No ]
  The PANSS is scale of 30 items which includes 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items). The scale ranges from 1 (absent) to 7 (extreme).
  
  
• Change from baseline in Positive And Negative Syndrome Scale (PANSS) Marder factor scores [ Time Frame: Baseline, Week 1, Week 5, Week 13 ] [ Designated as safety issue: No ]
  The PANSS is scale of 30 items which includes 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items). The scale ranges from 1 (absent) to 7 (extreme).
  
  
• Change from baseline in Positive And Negative Syndrome Scale (PANSS) subscale scores [ Time Frame: Baseline, Week 1, Week 5, Week 13 ] [ Designated as safety issue: No ]
  The PANSS is scale of 30 items which includes 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items). The scale ranges from 1 (absent) to 7 (extreme).
  
  
• Change from baseline in global severity of illness using the clinical global impression -severity (CGI-S) score [ Time Frame: Baseline, Week 1, Week 5, Week 9, Week 13 ] [ Designated as safety issue: No ]
  The CGI-S rating scale is used to rate the severity of a patient's overall clinical condition on a 7-point scale ranging from 1 to 7 where 1=Normal, not at all ill, 2=Borderline mentally ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, 7=Among the most extremely ill.
  
  
• Change from baseline in Personal and Social Performance (PSP) scale score [ Time Frame: Baseline, Week 13 ] [ Designated as safety issue: No ]
  The PSP assesses the degree of a patient's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Patients with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =<30, functioning so poorly as to require intensive supervision.
  
  
• Time to readiness for hospitalization discharge for inpatients using the Readiness for Discharge Questionnaire (RDQ) scale [ Time Frame: Baseline, Week 1, Week 5, Week 9, Week 13 ] [ Designated as safety issue: No ]
  The RDQ is developed on principally the Discharge RDQ consists of 6 items assessing suicidality/homicidality, control of aggression/impulsivity, activities of daily living, medication-taking, delusions/hallucinations interfering with functioning and global status.
  
  
• Number of patients with drug discontinuation [ Time Frame: Up to Week 13 ] [ Designated as safety issue: No ]
  

This is an open-label (all people know the identity of the intervention), prospective (looking forward using periodic observations collected predominantly following patient enrollment), non-comparative and multicenter study to evaluate the effectiveness and safety of paliperidone palmitate in acute schizophrenic patients. This study consists of a screening phase (up to 7 days), treatment phase (13 weeks), and a study completion or early withdrawal visit. Safety evaluations will include adverse events, clinical laboratory tests, concomitant medications, physical examination, and vital signs, which will be monitored throughout the study. The total duration of study participation for each patient will be approximately 13 weeks.